While BIM expression was increased in the majority of post-treatment samples tested (patient 23, sarcoma; 27 and 31, melanoma; and 33, pancreas; p < 0.05), consistent with evidence of MAPK blockade, clear trends in BCL-2 expression were not observed. Here, BCL2L11 is linked to sarcoma.